Actelion (Actelion) EBIT per Share : $7.51 (TTM As of Mar. 2017)

View and export this data going back to . Start your Free Trial

What is Actelion EBIT per Share?

Actelion's EBIT per Share for the three months ended in Mar. 2017 was $2.02. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2017 was $7.51.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Actelion's EBIT per Share or its related term are showing as below:

ALIOF's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.4
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Actelion's EBIT for the three months ended in Mar. 2017 was $214 Mil.

Actelion EBIT per Share Historical Data

The historical data trend for Actelion's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actelion EBIT per Share Chart

Actelion Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

EBIT per Share

Get a 7-Day Free Trial

3.68

4.55

4.82

5.86

7.18

Actelion Quarterly Data
	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
EBIT per Share	Get a 7-Day Free Trial															1.95	1.95	2.36	1.19	2.02

Actelion EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Actelion's EBIT per Share for the fiscal year that ended in Dec. 2016 is calculated as

	EBIT per Share		(A: Dec. 2016 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	773.702	/	107.811
=	7.18

Actelion's EBIT per Share for the quarter that ended in Mar. 2017 is calculated as

	EBIT per Share		(Q: Mar. 2017 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	214.125	/	106.114
=	2.02

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.51

Actelion (OTCPK:ALIOF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Actelion EBIT per Share Related Terms

Thank you for viewing the detailed overview of Actelion's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Actelion (Actelion) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actelion Ltd (OTCPK:ALIOF) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.actelion.com

Actelion is a Swiss biopharmaceutical firm with several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods of administration. Zavesca is a second-line option for Gaucher disease, and Valchlor treats a rare form of blood cancer. Actelion has created a global commercial infrastructure for its approved orphan drugs and has supplemented its internal pipeline through in-licensing and acquisitions.

Actelion (Actelion) Headlines

From GuruFocus

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon • 02-14-2017

Jean Hynes Reduces Stake in Actelion

By Kyle Ferguson Kyle Ferguson • 08-03-2016

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon • 01-24-2017

Actelion Still On Growth Track

By reports.droy reports.droy • 02-18-2015